Sugi Predict

Sugi Predict / Compounds / SCHEMBL17630680

SCHEMBL17630680

SCHEMBL17630680

CC(C)(C)OC(=O)N1CC[C@@H](O)C(F)(F)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.47
▸ RECQL P46063 1/20 0.44
▸ EPHX1 P07099 1/20 0.44
▸ USP2 O75604 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ GPR119 Q8TDV5 4/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ PTPN2 P17706 1/20 0.41
▸ PTPN1 P18031 1/20 0.41
▸ PTPN6 P29350 1/20 0.41
▸ CHRM2 P08172 1/20 0.41
▸ CHRM1 P11229 1/20 0.41
▸ CHRM3 P20309 1/20 0.41
▸ DDB1 Q16531 1/20 0.40
▸ CRBN Q96SW2 1/20 0.40
▸ STS P08842 1/20 0.40
▸ EPHX2 P34913 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1965038 1.00 HPGD (0.47) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL17630844 1.00 HPGD (0.47) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL31080158 0.86 EPHX1 (0.47) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL25901853 0.86 EPHX1 (0.47) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL15740632 0.86 EPHX1 (0.47) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL25901936 0.86 EPHX1 (0.47) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL31080572 0.86 EPHX1 (0.47) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL19506483 0.84 HPGD (0.47) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL17499855 0.84 NR1H2 (0.43) HPGDRECQLUSP2SMN1; SMN2CHRM2
SCHEMBL16714648 0.84 NR1H2 (0.43) HPGDRECQLUSP2SMN1; SMN2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4353715-B1 6-SUBSTITUTED CHIRALLY PURE DIFLUOROPIPERIDINE QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR WEISHANG SHANGHAI BIO PHARMACEUTICAL CO LTD (CN) 2026-04-15 — — EP disclosed
EP-4695238-A1 CDK2 INHIBITORS Blueprint Medicines Corporation (US) 2026-02-18 — — EP disclosed
US-20250092015-A1 A 6-substituted Chiral Pure Difluoropiperidine Quinazoline Derivative And Its Preparation Method WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) 2025-03-20 — — US disclosed
WO-2024245193-A1 HETEROAROMATIC RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 上海艾力斯医药科技股份有限公司 2024-12-05 — — WO disclosed
WO-2024216154-A1 CDK2 INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2024-10-17 — — WO disclosed
US-20240158392-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES JANSSEN RESEARCH & DEVELOPMENT, LLC 2024-05-16 — — US disclosed
EP-4353715-A1 6-SUBSTITUTED CHIRALLY PURE DIFLUOROPIPERIDINE QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) 2024-04-17 — — EP disclosed
WO-2024016783-A1 6-SUBSTITUTED CHIRALLY PURE DIFLUOROPIPERIDINE QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR 威尚（上海）生物医药有限公司 2024-01-25 — — WO disclosed
CN-115260153-B 6-substituted chiral pure difluoropiperidine quinazoline derivative and preparation method thereof 威尚（上海）生物医药有限公司 2023-10-27 — — CN disclosed
CN-115260153-A 6-substituted chiral pure difluoropiperidine quinazoline derivative and preparation method thereof 威尚（上海）生物医药有限公司 2022-11-01 — — CN disclosed
WO-2021179274-A1 ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS SUZHOU ZANRONG PHARMA LTD. (CN) 2021-09-16 — — WO disclosed
EP-3517536-B1 AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS GILEAD SCIENCES INC (US) 2021-05-05 — — EP disclosed
CN-111377850-A Chiral N-substituted-3, 3-difluoro-4-hydroxypiperidine derivative and preparation method thereof 扬州氟药科技有限公司 2020-07-07 — — CN disclosed
EP-3517536-A1 AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS Gilead Sciences, Inc. (US) 2019-07-31 — — EP disclosed
US-10253019-B2 Tank-binding kinase inhibitor compounds GILEAD SCIENCES, INC. (US) 2019-04-09 — — US disclosed
US-20180370955-A1 TANK-BINDING KINASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2018-12-27 — — US disclosed
US-10040781-B2 Tank-binding kinase inhibitor compounds GILEAD SCIENCES, INC. (US) 2018-08-07 — — US disclosed
EP-3197884-A1 AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS Gilead Sciences, Inc. (US) 2017-08-02 — — EP disclosed
US-20160096827-A1 TANK-BINDING KINASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2016-04-07 — — US disclosed
WO-2016049211-A1 AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2016-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180370955-A1 TANK-BINDING KINASE INHIBITOR COMPOUNDS TBKBP1, TNKS1BP1, TNKS HPGD 4072/4885RECQL 2586/4885EPHX1 4038/4885
US-20240158392-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES SIK2, SIK1, SGK2 HPGD 2441/4885RECQL 2513/4885EPHX1 3771/4885
US-10253019-B2 Tank-binding kinase inhibitor compounds TBKBP1, TNKS1BP1, TNKS HPGD 4072/4885RECQL 2586/4885EPHX1 4038/4885
US-10040781-B2 Tank-binding kinase inhibitor compounds TBKBP1, TNKS1BP1, TNKS HPGD 4072/4885RECQL 2586/4885EPHX1 4038/4885
US-20250092015-A1 A 6-substituted Chiral Pure Difluoropiperidine Quinazoline Derivative And Its Preparation Method CYP2D6, QDPR, FDPS HPGD 1482/4885RECQL 413/4885EPHX1 3611/4885
US-20160096827-A1 TANK-BINDING KINASE INHIBITOR COMPOUNDS TBKBP1, TNKS1BP1, TNKS HPGD 4072/4885RECQL 2586/4885EPHX1 4038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.